tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Phathom Pharmaceuticals (PHAT)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rhythm Pharmaceuticals (RYTMResearch Report) and Phathom Pharmaceuticals (PHATResearch Report) with bullish sentiments.

Rhythm Pharmaceuticals (RYTM)

Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Rhythm Pharmaceuticals today and set a price target of $15.00. The company’s shares closed last Tuesday at $8.49, close to its 52-week low of $6.02.

According to TipRanks.com, Higgins is a 3-star analyst with an average return of 3.7% and a 30.1% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Armata Pharmaceuticals, and Viridian Therapeutics.

Currently, the analyst consensus on Rhythm Pharmaceuticals is a Moderate Buy with an average price target of $23.50, a 198.6% upside from current levels. In a report issued on February 17, Needham also reiterated a Buy rating on the stock with a $50.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Phathom Pharmaceuticals (PHAT)

In a report released today, Joseph Stringer from Needham reiterated a Buy rating on Phathom Pharmaceuticals, with a price target of $55.00. The company’s shares closed last Tuesday at $18.13, close to its 52-week low of $14.04.

According to TipRanks.com, Stringer is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -25.0% and a 21.6% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Lexicon Pharmaceuticals, and Vertex Pharmaceuticals.

Currently, the analyst consensus on Phathom Pharmaceuticals is a Moderate Buy with an average price target of $55.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on RYTM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More